Relenza, the new flu treatment controversially excluded from the NHS because
a panel decided it was not cost-effective, can cause breathing difficulties in
patients with asthma. Glaxo Wellcome, which makes the drug, warned doctors of
the danger last week. The company says the number of people who have suffered
breathing difficulties after taking the drug is tiny, and that the warning is
simply a precaution. But the news is unfortunate, given that flu patients with
chronic lung disease are among the ones most likely to benefit from effective
influenza treatments.
To continue reading, today with our introductory offers
Advertisement
More from New Scientist
Explore the latest news, articles and features
Popular articles
Trending New Scientist articles
1
Woman with Alzheimer's starts conversing again after taking psilocybin
2
Possible signs of ancient life on Mars are rich in complex carbon
3
Screwworm could be the first species targeted by an 'extinction drive'
4
You should turn off fans when it's too hot – but how hot is too hot?
5
Unapproved gene therapy for boosting longevity is set to go on sale
6
Most portable air conditioners suck – but there's an easy fix
7
All known Homo naledi skeletons seem to be female
8
‘Fusogenic’ neurosurgery let paralysed pigs walk again – are we next?
9
Hidden black hole could explain mystery at the heart of our galaxy
10
How some people's brains make an extraordinary recovery from stroke



